The 340B program “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicted this week during a talk on drug pricing reform at the 340B Coalition virtual summer conference.
“I do want to stress, manufacturers are talking about some kind of grand bargain on drug pricing,” said McCaughan, a contributor to and the former editor-in-chief of The Pink Sheet, a leading drug industry trade publication. “They will not be overlooking the 340B program. None of you will be overlooking the 340B program either. It’s going to be an important part of the conversation.”
The 340B program “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicted this week during a talk on drug pricing reform at the 340B Coalition virtual summer conference.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.